Biotinylated Human CD19, Fc Tag, ultra sensitivity (primary amine labeling)

Source : 

MABSol® Biotinylated Human CD19, Fc Tag, primary amine labeling (CD9-H8259) is expressed from human HEK293 cells. It contains AA Pro 20 - Lys 291 (Accession # P15391-1). It is the biotinylated form of Human CD19, Fc Tag (Cat. No. CD9-H5259).

 

Molecule : CD19

 

Synonyms : CD19,B4,CVID3,MGC12802

 

Format : Powder

 

Category : MABSol® Biotin Labeled Proteins

 

Accession : NP_001761.3

 

Storage : -20℃

 

Shipping condition : Powder,RT

 

Molecular Weight : 56.3 kDa

 

Characteristics :

This protein carries a human IgG1 Fc fragment at the C-terminus. The protein has a calculated MW of 56.3 kDa. The protein migrates as 60-90 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation.

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : PBS, pH7.4

 

Description :

B-lymphocyte antigen CD19, is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

 

References :

(1) Pesando JM, et al., J. Exp. Med. 170 (6): 2159–64.
(2) van Zelm MC, et al., 2006, N. Engl. J. Med. 354 (18): 1901–12.
(3) Bradbury LE, et al., 1992, J. Immunol. 149 (9): 2841–50.
(4) Horváth G, et al., 1998, J. Biol. Chem. 273 (46): 30537–43.
(5) Imai T, et al., 1995, J. Immunol. 155 (3): 1229–39.
(6) Doody GM, et al., 2000, EMBO J. 19 (22): 6173–84.